There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Kura Oncology (KURA – Research Report) and Siemens Healthineers AG (SEMHF – Research Report) with bullish sentiments.
Kura Oncology (KURA)
Barclays analyst Peter Lawson maintained a Buy rating on Kura Oncology yesterday and set a price target of $47.00. The company’s shares closed last Thursday at $13.50.
According to TipRanks.com, Lawson is a 3-star analyst with an average return of 1.2% and a 42.7% success rate. Lawson covers the Healthcare sector, focusing on stocks such as Adaptimmune Therapeutics, Springworks Therapeutics, and Iovance Biotherapeutics.
Kura Oncology has an analyst consensus of Strong Buy, with a price target consensus of $30.38, a 127.4% upside from current levels. In a report issued on May 23, Stifel Nicolaus also maintained a Buy rating on the stock with a $24.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Siemens Healthineers AG (SEMHF)
In a report released today, Odysseas Manesiotis from Berenberg Bank maintained a Buy rating on Siemens Healthineers AG, with a price target of EUR58.00. The company’s shares closed last Wednesday at $56.90.
Manesiotis has an average return of 3.8% when recommending Siemens Healthineers AG.
According to TipRanks.com, Manesiotis is ranked #8016 out of 8379 analysts.
Siemens Healthineers AG has an analyst consensus of Moderate Buy, with a price target consensus of $64.79, representing a 13.9% upside. In a report issued on May 19, Bernstein also maintained a Buy rating on the stock with a EUR60.50 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on KURA: